209837327
Menu
Your Cart
UK Based - We ship to the EU, the USA, Australia, New Zealand - in fact we ship WORLDWIDE! Please see our FAQ/Terms for specifics if needed. NEW DEDICATED CUSTOMER SERVICE EMAIL: customerservice@peptex-labs.com
NEW: TELERGRAM - GET A QUICK REPLY VIA TELEGRAM @PEPTEX
UK Based - We ship to the EU, the USA, Australia, New Zealand - in fact we ship WORLDWIDE! Please see our FAQ/Terms for specifics if needed.
*22/10/21 - we have sent orders out Friday 22/10 - tracking will be updated Monday 25/10 - thank you*
15% OFF all ORDERS if you choose to pay by bitcoin, discount code BTC15 - applicable for those who pay by Bitcoin only, anyone else will have their order deleted.

Peptex Laboratories NEW! Peptide YY 10mg x 10 vial package 99%>+ Purity

Peptex Laboratories NEW! Peptide YY 10mg x 10 vial package 99%>+ Purity
New
Peptex Laboratories NEW! Peptide YY 10mg x 10 vial package 99%>+ Purity
  • Stock: In Stock
  • Model: PEPYY
150 samples sold
18200 views
£495.00

Peptex Laboratories NEW - PEPTIDE YY 10mg

Note: this is a custom order - when you order this 10 vial package it is custom synthesised for you, tested with COA and sent to us directly. Once with us we conduct our own internal QC checks, prior to dispatch. In total this equates to approx 8-12 working day wait period. If you cannot wait for 2 weeks approx or are in urgent need, please do not order, thank you. Also note this item is a Special Edition so will come with a Special Edition Label and will have a data sheet folded within the sealed mylar foil pouch we now send our peptides in (+ adequate protective packaging)

To reconfirm this offering is for 10 vials of Peptide YY each containing 10mg.


Peptide YY (3-36) is a Y2 selective agonist. IC50 values are 0.11 and 1050 nM for inhibition of 125I-PYY binding to Y2 and Y1 receptors respectively. Inhibits food intake and reduces weight gain in vivo. Brain penetrant.


Peptide YY (PYY) also known as peptide tyrosine tyrosine is a peptide that in humans is encoded by the PYY gene. Peptide YY is a short (36-amino acid) peptide released from cells in the ileum and colon in response to feeding. In the blood, gut, and other elements of periphery, PYY acts to reduce appetite; similarly, when injected directly into the central nervous system, PYY is also anorexigenic, i.e., it reduces appetite.

Dietary fibres from fruits, vegetables, and whole grains, consumed, increase the speed of transit of intestinal chyme into the ileum, to raise PYY3-36, and induce satiety. Peptide YY can be produced as the result of enzymatic breakdown of crude fish proteins and ingested as a food product.

 

Structure

Peptide YY is related to the pancreatic peptide family by having 18 of its 36 amino acids located in the same positions as pancreatic peptide. The two major forms of peptide YY are PYY1-36 and PYY3-36, which have PP fold structural motifs. However, the most common form of circulating PYY immunoreactivity is PYY3-36, which binds to the Y2 receptor (Y2R) of the Y family of receptors. Peptide YY3-36 (PYY) is a linear polypeptide consisting of 34 amino acids with structural homology to NPY and pancreatic polypeptide.

 

Release

PYY is found in L cells in the mucosa of gastrointestinal tract, especially in ileum and colon. Also, a small amount of PYY, about 1-10%, is found in the oesophagus, stomach, duodenum and jejunum. PYY concentration in the circulation increases postprandially (after food ingestion) and decreases by fasting. In addition, PYY is produced by a discrete population of neurons in the brainstem, specifically localized to the gigantocellular reticular nucleus of the medulla oblongata. C. R. Gustavsen et al. had found PYY-producing cells located in the islets of Langerhans in rats. They were observed either alone or co-localized with glucagon or PP.

 

Function

PYY exerts its action through NPY receptors; it inhibits gastric motility and increases water and electrolyte absorption in the colon. PYY may also suppress pancreatic secretion. It is secreted by the neuroendocrine cells in the ileum and colon in response to a meal and has been shown to reduce appetite. PYY works by slowing the gastric emptying; hence, it increases efficiency of digestion and nutrient absorption after a meal. Research has also indicated PYY may be useful in removing aluminium accumulated in the brain.

 

Animal studies

Several studies have shown acute peripheral administration of PYY3-36 inhibits feeding of rodents and primates. Other studies on Y2R-knockout mice have shown no anorectic effect on them. These findings indicate PYY3-36 has an anorectic (losing appetite) effect, which is suggested to be mediated by Y2R. PYY-knockout female mice increase in body weight and fat mass. PYY-knockout mice, on the other hand, are resistant to obesity, but have higher fat mass and lower glucose tolerance when fed a high-fat diet, compared to control mice. Thus, PYY also plays a very important role in energy homeostasis by balancing food intake. PYY oral spray was found to promote fullness. Viral gene therapy of the salivary glands resulted in long-term intake reduction.

 

Relevance to obesity

Leptin also reduces appetite in response to feeding, but obese people develop a resistance to leptin. Obese people secrete less PYY than non-obese people and attempts to use PYY directly as a weight-loss drug have met with some success. Researchers noted the caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30% in obese subjects (P<0.001) and 31% in lean subjects (P<0.001).

While some studies have shown obese persons have lower circulating level of PYY postprandially, other studies have reported they have normal sensitivity to the anorectic effect of PYY3-36. Thus, reduction in PYY sensitivity may not be one of the causes of obesity, in contrast to the reduction of leptin sensitivity. The anorectic effect of PYY could possibly be a future obesity drug.

The consumption of protein boosts PYY levels, so some benefit was observed in experimental subjects in reducing hunger and promoting weight loss. This could partially explain the weight-loss experienced with high-protein diets, but the high thermic effect of protein appears to be the leading cause.

Obese patients undergoing gastric bypass showed marked metabolic adaptations, resulting in frequent diabetes remission 1 year later. When the confounding of calorie restriction is factored out, β-cell function improves rapidly, very possibly under the influence of enhanced GLP-1 responsiveness. Insulin sensitivity improves in proportion to weight loss, with a possible involvement of PYY.

Write a review

Note: HTML is not translated!
Bad Good

Unlimited Blocks, Tabs or Accordions with any HTML content can be assigned to any individual product or to certain groups of products, like entire categories, brands, products with specific options, attributes, price range, etc. You can indicate any criteria via the advanced product assignment mechanism and only those products matching your criteria will display the modules.

Also, any module can be selectively activated per device (desktop/tablet/phone), customer login status and other criteria. Imagine the possibilities. 

Your data, cookies & privacy
Your Privacy: Peptex-Labs.com use cookies by default through it’s shopping cart - while we use cookies we do not do so for any other reason than our base shopping cart software utilises cookies by default (Opencart.com). Should you require further info please contact us at peptexlabs@protonmail.com